罗氟司特常见副作用

Roflumilast should not be used to treat sudden dyspnea (acute bronchospasm) and is not recommended in persons <18 years of age. The most common adverse reactions reported by patients receiving roflumilast were diarrhea, nausea, headache, insomnia, back pain, decreased appetite, and dizziness. When the FDA approved roflumilast, it came with a medication guide that informed patients of potential risks to mental health, including mood changes, thinking changes, behavioral changes, and unexplained weight loss.

Although roflumilast can significantly reduce dyspnea symptoms in Asian patients with chronic obstructive pulmonary disease (COPD), it cannot improve the patients' FEV1/FVC. In terms of safety, roflumilast can increase the risk of diarrhea, respiratory tract infection, loss of appetite, weight loss, headache, dizziness, gastritis, and anorexia. Therefore, when roflumilast is used in Asian populations, the corresponding adverse reactions should be closely monitored and the drug should be used with caution.

The reason why roflumilast causes more adverse reactions may be that it can act on the four subtypes of PDE-4 (PDE-4A, PDE-4B, PDE-4C and PDE-4D) at the same time. However, only when inhibiting PDE-4B, it will produce bronchodilation and anti-inflammatory effects, while inhibiting PDE-4D will induce vomiting. This may be related to the large amount of PDE-4D in brain cells. Studies have shown that roflumilast, glucocorticoid drugs, and bronchodilators can reduce airway inflammation through different mechanisms of action. The combined use of these drugs can maximize the anti-inflammatory effect and reduce the hospitalization rate caused by acute exacerbations and acute attacks. However, in the later period, it may further increase the risk of patients with COPD acute exacerbations.

It is not currently listed in China, so it is not eligible for medical insurance. In other words, if patients want to purchase the drug, they must go abroad to purchase it. Traveling abroad to buy medicines is a long journey and requires a lot of manpower and material resources. Coupled with the huge medical expenses, many patient families are overwhelmed. However, according to Medical Companion Travel, 500μg*90 tablets of roflumilast costs approximately $2,850 per box. Since the exchange rate has been in a state of fluctuation for a long time, the price fluctuates with the exchange rate and is not static. For more information about roflumilast, please contact Medical Companion Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.